Valeriya V. Saevets
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Valeriya V. Saevets has a total of 136 co-authors. Here are the top co-authors by number of shared publications:
- Anna Yu. Shamanova
Chelyabinsk Regional Clinical Center of Oncology and Nuclear Medicine
10 shared publications - Nikita K. Kuzmin
Chelyabinsk Regional Clinical Center of Oncology and Nuclear Medicine
6 shared publications - L. V. Yarina
Chelyabinsk Regional Clinical Center of Oncology and Nuclear Medicine
4 shared publications A. A. Mukhin
Chelyabinsk Regional Clinical Center of Oncology and Nuclear Medicine
3 shared publications- A. V. Privalov
Chelyabinsk Regional Clinical Center of Oncology and Nuclear Medicine
3 shared publications A. V. Taratonov
Chelyabinsk Regional Clinical Center of Oncology and Nuclear Medicine
3 shared publications
Latest Publications
- Open Access
- 25 October 2026
- Published by Russian Society of Clinical Oncology in Malignant tumours
- Vol. 16 (3) , 104-110
Resolution on the results of the expert council on the topic “Expanding options for maintenance therapy of ovarian cancer: the place of the new PARP inhibitor Fuzuloparib in Russian clinical guidelines”
Expert advisory board meetings were held on April 2, 2026, and July 3, 2026, during which the country’s leading oncologists discussed the current state of pharmacological therapy for ovarian cancer and the prospects for introducing a new selective PARP inhibitor, fuzuloparib. The treatment of malignant ovarian neoplasms remains one of the most challenging areas in gynecologic oncology. Although ovarian cancer ranks third in incidence—following endometrial and cervical cancers—it firmly holds the top spot in terms of mortality. Approximately 14,000 new cases are diagnosed annually in Russia, with over 40% of patients diagnosed at advanced stages (III–IV). The advent of PARP inhibitors has fundamentally transformed the maintenance therapy paradigm for BRCA-associated and HRD-positive cancers; however, the availability of this class of drugs in the Russian Federation remains limited, and current practice necessitates an expansion of therapeutic options.
- 25 October 2026
- Published by Russian Society of Clinical Oncology in Malignant tumours
- Vol. 16 (3) , 104-110
Open AccessResolution on the results of the expert council on the topic “Expanding options for maintenance therapy of ovarian cancer: the place of the new PARP inhibitor Fuzuloparib in Russian clinical guidelines”
Expert advisory board meetings were held on April 2, 2026, and July 3, 2026, during which the country’s leading oncologists discussed the current state of pharmacological therapy for ovarian cancer and the prospects for introducing a new selective PARP inhibitor, fuzuloparib. The treatment of malignant ovarian neoplasms remains one of the most challenging areas in gynecologic oncology. Although ovarian cancer ranks third in incidence—following endometrial and cervical cancers—it firmly holds the top spot in terms of mortality. Approximately 14,000 new cases are diagnosed annually in Russia, with over 40% of patients diagnosed at advanced stages (III–IV). The advent of PARP inhibitors has fundamentally transformed the maintenance therapy paradigm for BRCA-associated and HRD-positive cancers; however, the availability of this class of drugs in the Russian Federation remains limited, and current practice necessitates an expansion of therapeutic options.
- Open Access
- 20 October 2026
- Published by Publishing House ABV Press in Tumors of female reproductive system
- Vol. 22 (2) , 67-74
Assessment of quality of life in patients with advanced ovarian cancer after peritoneal port system implantation
Background. Refractory ascites complicating advanced recurrent ovarian cancer (OC) leads to a marked deterioration in quality of life and an unfavorable oncological prognosis. The implementation of clinically effective approaches to ascites control remains an important objective in palliative gynecologic oncology. Aim. To evaluate the outcomes of implantable peritoneal port-system placement based on quality-of-life measures in patients with progressive OC within a prospective single-arm study. Materials and methods. A prospective single-arm study was conducted at the Chelyabinsk Regional Clinical Center of Oncology and Nuclear Medicine and included 75 patients with OC who underwent implantation of a peritoneal port system. The primary endpoint was the change in the total FACT-G (Functional Assessment of Cancer Therapy – General) score 30 days after implantation. Secondary endpoints included changes in the individual FACT-G domain scores: physical, social / family, emotional, and functional well-being, as well as the incidence of postoperative complications. Quality of life before and after the intervention was assessed using the validated FACT-G questionnaire. Results. The median total FACT-G score increased from 66 [65; 68.5] to 89 [88; 91] points. The median paired change was 23 points (95 % confidence interval 22–25; W = 0; p 0.001). A clinically meaningful improvement of at least 7 points was observed in all 75 patients (100 %; 95 % confidence interval 95.2–100). Statistically significant positive changes were found across all assessed domains. During the 30-day follow-up period, 1 (1.3 %) case of port system infection was recorded, requiring its removal. Conclusion. Implantation of peritoneal port systems was associated with substantial clinical benefit in patients with recurrent OC and clinically significant ascites. The procedure is technically straightforward, well tolerated, and is not associated with the clinically significant complications commonly observed with repeated paracentesis, which is particularly important in the provision of palliative care. However, the study was conducted without a control group, limiting the ability to establish a causal relationship between port-system implantation and improvement in quality of life.
- 20 October 2026
- Published by Publishing House ABV Press in Tumors of female reproductive system
- Vol. 22 (2) , 67-74
Open AccessAssessment of quality of life in patients with advanced ovarian cancer after peritoneal port system implantation
Background. Refractory ascites complicating advanced recurrent ovarian cancer (OC) leads to a marked deterioration in quality of life and an unfavorable oncological prognosis. The implementation of clinically effective approaches to ascites control remains an important objective in palliative gynecologic oncology. Aim. To evaluate the outcomes of implantable peritoneal port-system placement based on quality-of-life measures in patients with progressive OC within a prospective single-arm study. Materials and methods. A prospective single-arm study was conducted at the Chelyabinsk Regional Clinical Center of Oncology and Nuclear Medicine and included 75 patients with OC who underwent implantation of a peritoneal port system. The primary endpoint was the change in the total FACT-G (Functional Assessment of Cancer Therapy – General) score 30 days after implantation. Secondary endpoints included changes in the individual FACT-G domain scores: physical, social / family, emotional, and functional well-being, as well as the incidence of postoperative complications. Quality of life before and after the intervention was assessed using the validated FACT-G questionnaire. Results. The median total FACT-G score increased from 66 [65; 68.5] to 89 [88; 91] points. The median paired change was 23 points (95 % confidence interval 22–25; W = 0; p 0.001). A clinically meaningful improvement of at least 7 points was observed in all 75 patients (100 %; 95 % confidence interval 95.2–100). Statistically significant positive changes were found across all assessed domains. During the 30-day follow-up period, 1 (1.3 %) case of port system infection was recorded, requiring its removal. Conclusion. Implantation of peritoneal port systems was associated with substantial clinical benefit in patients with recurrent OC and clinically significant ascites. The procedure is technically straightforward, well tolerated, and is not associated with the clinically significant complications commonly observed with repeated paracentesis, which is particularly important in the provision of palliative care. However, the study was conducted without a control group, limiting the ability to establish a causal relationship between port-system implantation and improvement in quality of life.
- Open Access
- 28 August 2026
- Published by Russian Society of Clinical Oncology in Malignant tumours
- Vol. 16 (2) , 97-107
Sebaceous carcinoma of the vulva: a clinical case and a literature review
Background. Vulvar cancer (VC) is a rare malignancy in women, accounting for no more than 4 % of all cancers. Sebaceous histologic subtypes of VC are exceptionally uncommon. We summarize our own experience and that of other authors regarding presentation, diagnosis, and management. Objective. To present a clinical case of vulvar sebaceous carcinoma and synthesize the available literature to clarify the clinicopathologic features, diagnostics, treatment, and prognosis of this malignancy. Materials and Methods. We described a clinical case of vulvar sebaceous carcinoma treated at our center. In addition, we conducted a systematic literature review (PubMed, MEDLINE, Cochrane Library, eLibrary.ru; 1970–2025; keywords “sebaceous carcinoma”, “vulvar cancer”) of published cases. Results. Immunohistochemistry confirmed sebaceous carcinoma (EMA+, pan-CK+, S100 / Melan-A–); stage IB (pT1bN0M0). A hemivulvectomy achieved a clear margin ≥ 10 mm; no adjuvant therapy was given; at 21‑month follow-up there was no recurrence. The literature review of 16 cases showed that the vast majority of patients (~ 80 %) underwent surgical treatment; inguinal lymph-node metastases were reported in ~ 20 %, and distant metastases in < 10 %. In isolated reports, adjuvant radiotherapy and immunotherapy (PD-1 inhibitors) were used for advanced disease. Conclusion . Vulvar sebaceous carcinoma is exceedingly rare and insufficiently studied, requiring an individualized, multidisciplinary approach. In localized stages, radical surgical excision provides a favorable prognosis. Regional lymph-node assessment is preferably performed via sentinel lymph-node biopsy, and all patients should undergo immunohistochemical evaluation of the mismatch-repair (MMR) system to exclude Muir — Torre syndrome and to determine eligibility for targeted and / or immunotherapy.
- 28 August 2026
- Published by Russian Society of Clinical Oncology in Malignant tumours
- Vol. 16 (2) , 97-107
Open AccessSebaceous carcinoma of the vulva: a clinical case and a literature review
Background. Vulvar cancer (VC) is a rare malignancy in women, accounting for no more than 4 % of all cancers. Sebaceous histologic subtypes of VC are exceptionally uncommon. We summarize our own experience and that of other authors regarding presentation, diagnosis, and management. Objective. To present a clinical case of vulvar sebaceous carcinoma and synthesize the available literature to clarify the clinicopathologic features, diagnostics, treatment, and prognosis of this malignancy. Materials and Methods. We described a clinical case of vulvar sebaceous carcinoma treated at our center. In addition, we conducted a systematic literature review (PubMed, MEDLINE, Cochrane Library, eLibrary.ru; 1970–2025; keywords “sebaceous carcinoma”, “vulvar cancer”) of published cases. Results. Immunohistochemistry confirmed sebaceous carcinoma (EMA+, pan-CK+, S100 / Melan-A–); stage IB (pT1bN0M0). A hemivulvectomy achieved a clear margin ≥ 10 mm; no adjuvant therapy was given; at 21‑month follow-up there was no recurrence. The literature review of 16 cases showed that the vast majority of patients (~ 80 %) underwent surgical treatment; inguinal lymph-node metastases were reported in ~ 20 %, and distant metastases in < 10 %. In isolated reports, adjuvant radiotherapy and immunotherapy (PD-1 inhibitors) were used for advanced disease. Conclusion . Vulvar sebaceous carcinoma is exceedingly rare and insufficiently studied, requiring an individualized, multidisciplinary approach. In localized stages, radical surgical excision provides a favorable prognosis. Regional lymph-node assessment is preferably performed via sentinel lymph-node biopsy, and all patients should undergo immunohistochemical evaluation of the mismatch-repair (MMR) system to exclude Muir — Torre syndrome and to determine eligibility for targeted and / or immunotherapy.
- Open Access
- 20 January 2026
- Published by Publishing House ABV Press in Tumors of female reproductive system
- Vol. 21 (4) , 91-98
Surgical treatment of vulvar cancer: results of a pilot study implementing a new lymph node classification and a brief literature review
Background. Vulvar cancer is a rare oncological disease, accounting for about 4 % of all malignant neoplasms of the female reproductive system. A characteristic feature of this disease is the predominant involvement of elderly women, which complicates treatment due to the presence of concomitant pathology. Standard surgical treatment, including radical vulvectomy with inguinal-femoral lymphadenectomy (LAE), is traditionally associated with a high risk of postoperative complications. This necessitates the development and implementation of less invasive approaches that can reduce the frequency of complications while maintaining oncological radicality. Aim. To implement and evaluate the effectiveness of a new classification of LAE volumes, developed to reduce the frequency of postoperative complications in patients with vulvar cancer. Materials and methods. The study included 37 patients with a morphologically verified diagnosis of stage IB vulvar cancer. Depending on tumor characteristics and data from instrumental research methods, patients underwent various interventions on the inguinal-femoral lymph nodes: signal lymph node biopsy using technetium (n = 10), superficial (modified) inguinal-femoral LAE (n = 13), or classical inguinal-femoral LAE (n = 14). All patients underwent radical vulvectomy. Results. Analysis of the postoperative period showed that in the groups with signal node biopsy and superficial LAE, there were no postoperative complications. At the same time, in the classical inguinal-femoral LAE group, complications were recorded in 50 % of patients. Metastatic lymph node involvement was detected in 7.6 % of cases in the superficial LAE group and in 14.2 % of cases in the classical LAE group. During the follow-up period, no disease recurrences were noted in the groups with sentinel node biopsy and superficial LAE. Conclusion. А personalized approach to selecting the extent of LAE based on the proposed classification, which takes into account the size and location of the primary tumor, significantly reduces the frequency of postoperative complications while maintaining oncological radicality.
- 20 January 2026
- Published by Publishing House ABV Press in Tumors of female reproductive system
- Vol. 21 (4) , 91-98
Open AccessSurgical treatment of vulvar cancer: results of a pilot study implementing a new lymph node classification and a brief literature review
Background. Vulvar cancer is a rare oncological disease, accounting for about 4 % of all malignant neoplasms of the female reproductive system. A characteristic feature of this disease is the predominant involvement of elderly women, which complicates treatment due to the presence of concomitant pathology. Standard surgical treatment, including radical vulvectomy with inguinal-femoral lymphadenectomy (LAE), is traditionally associated with a high risk of postoperative complications. This necessitates the development and implementation of less invasive approaches that can reduce the frequency of complications while maintaining oncological radicality. Aim. To implement and evaluate the effectiveness of a new classification of LAE volumes, developed to reduce the frequency of postoperative complications in patients with vulvar cancer. Materials and methods. The study included 37 patients with a morphologically verified diagnosis of stage IB vulvar cancer. Depending on tumor characteristics and data from instrumental research methods, patients underwent various interventions on the inguinal-femoral lymph nodes: signal lymph node biopsy using technetium (n = 10), superficial (modified) inguinal-femoral LAE (n = 13), or classical inguinal-femoral LAE (n = 14). All patients underwent radical vulvectomy. Results. Analysis of the postoperative period showed that in the groups with signal node biopsy and superficial LAE, there were no postoperative complications. At the same time, in the classical inguinal-femoral LAE group, complications were recorded in 50 % of patients. Metastatic lymph node involvement was detected in 7.6 % of cases in the superficial LAE group and in 14.2 % of cases in the classical LAE group. During the follow-up period, no disease recurrences were noted in the groups with sentinel node biopsy and superficial LAE. Conclusion. А personalized approach to selecting the extent of LAE based on the proposed classification, which takes into account the size and location of the primary tumor, significantly reduces the frequency of postoperative complications while maintaining oncological radicality.
- Open Access
- 5 December 2025
- Published by Consilium Medicum in Journal of Modern Oncology
- Vol. 27 (3) , 267-274
New approaches in the treatment of aggressive subtypes of endometrial cancer and the prognostic role of HER2 status of the tumor: A systematic review
Background. Endometrial cancer (EC) remains one of the most pressing problems in gynecological oncology. Aggressive histological subtypes of EC (serous, clear cell, carcinosarcoma) are characterized by an insufficient response to standard therapy and a poor prognosis. The above subtypes have a high rate (up to 49%) of HER2 positivity and a strong association with the p53-aberrant molecular profile, which presents potential opportunities for targeted therapy. Aim. To review current data on approaches to the diagnosis of HER2 status, the effectiveness of anti-HER2 therapy, and the prognostic role of HER2 status of the tumor in aggressive subtypes of EC. Materials and methods. A systematic search of publications was conducted in the PubMed, MEDLINE, Cochrane Library, and Elibrary.ru databases for 2000–2024. Key words and their combinations were used: “endometrial cancer,” “serous carcinoma,” “carcinosarcoma,” “HER2,” “ERBB2,” “targeted therapy,” “trastuzumab,” “trastuzumab deruxtecan,” “disitamab vedotin,” “endometrial cancer,” “uterine serous carcinoma,” “carcinosarcoma,” “HER2-positive,” “targeted therapy.” The inclusion criteria were met by original studies, literature reviews, meta-analyses, and case reports on the prevalence of HER2 positivity, the efficacy of anti-HER2 therapy, and the prognostic role of HER2 status in aggressive histologic subtypes of EC. Excluded from the search were articles that have not been reviewed, as well as publications that do not report data on methods for determining HER2 status (immunohistochemistry, FISH method) or response to treatment. Results. Significant heterogeneity of HER2 expression was found with a maximum frequency in serous EC (49%) and carcinosarcoma (40%). HER2-positivity has been shown to be associated with a 45% reduction in overall survival (HR 2.1, 95% CI 1.4-3.2; p0,001). Therapeutic studies have demonstrated the high efficacy of trastuzumab in combination with chemotherapy in the primary treatment of serous EC (median progression-free survival 17.9 months vs 9.3 months, HR 0.40; p=0.013). Trastuzumab deruxtecan showed significant activity even with expression of HER2 2+ (objective response rate 25-70% with of HER2 expression level 2+), with a median overall survival 26.0 months with HER2 expression 3+. The problems of standardization of HER2 testing and heterogeneity of expression are revealed. Conclusion. HER2-targeted therapy has become the new standard of treatment for aggressive subtypes of EC. The greatest effectiveness was achieved when using antibody conjugates with cytostatics, especially with HER2 overexpression. The development of unified HER2 testing standards, overcoming resistance, and optimizing combined modes are critically important areas. The perspectives are related to the adaptation of therapy to molecular subtypes and the identification of response predictors.
- 5 December 2025
- Published by Consilium Medicum in Journal of Modern Oncology
- Vol. 27 (3) , 267-274
Open AccessNew approaches in the treatment of aggressive subtypes of endometrial cancer and the prognostic role of HER2 status of the tumor: A systematic review
Background. Endometrial cancer (EC) remains one of the most pressing problems in gynecological oncology. Aggressive histological subtypes of EC (serous, clear cell, carcinosarcoma) are characterized by an insufficient response to standard therapy and a poor prognosis. The above subtypes have a high rate (up to 49%) of HER2 positivity and a strong association with the p53-aberrant molecular profile, which presents potential opportunities for targeted therapy. Aim. To review current data on approaches to the diagnosis of HER2 status, the effectiveness of anti-HER2 therapy, and the prognostic role of HER2 status of the tumor in aggressive subtypes of EC. Materials and methods. A systematic search of publications was conducted in the PubMed, MEDLINE, Cochrane Library, and Elibrary.ru databases for 2000–2024. Key words and their combinations were used: “endometrial cancer,” “serous carcinoma,” “carcinosarcoma,” “HER2,” “ERBB2,” “targeted therapy,” “trastuzumab,” “trastuzumab deruxtecan,” “disitamab vedotin,” “endometrial cancer,” “uterine serous carcinoma,” “carcinosarcoma,” “HER2-positive,” “targeted therapy.” The inclusion criteria were met by original studies, literature reviews, meta-analyses, and case reports on the prevalence of HER2 positivity, the efficacy of anti-HER2 therapy, and the prognostic role of HER2 status in aggressive histologic subtypes of EC. Excluded from the search were articles that have not been reviewed, as well as publications that do not report data on methods for determining HER2 status (immunohistochemistry, FISH method) or response to treatment. Results. Significant heterogeneity of HER2 expression was found with a maximum frequency in serous EC (49%) and carcinosarcoma (40%). HER2-positivity has been shown to be associated with a 45% reduction in overall survival (HR 2.1, 95% CI 1.4-3.2; p0,001). Therapeutic studies have demonstrated the high efficacy of trastuzumab in combination with chemotherapy in the primary treatment of serous EC (median progression-free survival 17.9 months vs 9.3 months, HR 0.40; p=0.013). Trastuzumab deruxtecan showed significant activity even with expression of HER2 2+ (objective response rate 25-70% with of HER2 expression level 2+), with a median overall survival 26.0 months with HER2 expression 3+. The problems of standardization of HER2 testing and heterogeneity of expression are revealed. Conclusion. HER2-targeted therapy has become the new standard of treatment for aggressive subtypes of EC. The greatest effectiveness was achieved when using antibody conjugates with cytostatics, especially with HER2 overexpression. The development of unified HER2 testing standards, overcoming resistance, and optimizing combined modes are critically important areas. The perspectives are related to the adaptation of therapy to molecular subtypes and the identification of response predictors.
- Open Access
- 17 July 2025
- Published by Consilium Medicum in Journal of Modern Oncology
- Vol. 27 (2) , 65-71
Intermediate results of the PERFECTION observational study in a population of patients with metastatic, persistent and recurrent cervical cancer
Background. Cervical cancer (CC) is among the four most common malignancies among the female population. For a long time, platinum-based chemotherapy was the standard of care and practically the only option available. However, treatment outcomes for patients with metastatic and recurrent CC remained poor. The use of immune checkpoint inhibitors significantly increased progression-free survival and overall survival in this group of patients. Currently, pembrolizumab is a priority option in treating patients with metastatic, persistent, recurrent CC with CPS ≥ 1 and is included in international and Russian clinical guidelines. Aim. To evaluate the efficacy and safety of a pembrolizumab biosimilar (Pembroria®) in patients with metastatic, persistent and recurrent CC in the interim analysis of the PERFECTION observational study. Materials and methods. The study included a group of 51 patients diagnosed with stage IV CC. The treatment efficacy was analyzed using the Fleming method with the objective response rate criterion according to RECIST 1.1. Safety was assessed by the incidence of adverse events (AEs) and serious AEs according to the CTCAE 5.0 toxicity scale. Results. At stage g2, an objective response was reported in 24 (47.1%) patients, which exceeded the target threshold (22 responses). 5 (9.8%) patients experienced immune-mediated AEs, a total of 6 cases, including 1 case of grade 3 AE. The overall objective response rate was consistent with KEYNOTE-826, but the AE rate was lower (34.5% in KEYNOTE-826). Conclusion. Pembroria® has demonstrated efficacy comparable to that of the original pembrolizumab product and an acceptable safety profile. Differences in the incidence of immune-mediated AEs associated with Pembroria® require further study, considering the duration of observation and sample size. The results support using Pembroria® in routine clinical practice.
- 17 July 2025
- Published by Consilium Medicum in Journal of Modern Oncology
- Vol. 27 (2) , 65-71
Open AccessIntermediate results of the PERFECTION observational study in a population of patients with metastatic, persistent and recurrent cervical cancer
Background. Cervical cancer (CC) is among the four most common malignancies among the female population. For a long time, platinum-based chemotherapy was the standard of care and practically the only option available. However, treatment outcomes for patients with metastatic and recurrent CC remained poor. The use of immune checkpoint inhibitors significantly increased progression-free survival and overall survival in this group of patients. Currently, pembrolizumab is a priority option in treating patients with metastatic, persistent, recurrent CC with CPS ≥ 1 and is included in international and Russian clinical guidelines. Aim. To evaluate the efficacy and safety of a pembrolizumab biosimilar (Pembroria®) in patients with metastatic, persistent and recurrent CC in the interim analysis of the PERFECTION observational study. Materials and methods. The study included a group of 51 patients diagnosed with stage IV CC. The treatment efficacy was analyzed using the Fleming method with the objective response rate criterion according to RECIST 1.1. Safety was assessed by the incidence of adverse events (AEs) and serious AEs according to the CTCAE 5.0 toxicity scale. Results. At stage g2, an objective response was reported in 24 (47.1%) patients, which exceeded the target threshold (22 responses). 5 (9.8%) patients experienced immune-mediated AEs, a total of 6 cases, including 1 case of grade 3 AE. The overall objective response rate was consistent with KEYNOTE-826, but the AE rate was lower (34.5% in KEYNOTE-826). Conclusion. Pembroria® has demonstrated efficacy comparable to that of the original pembrolizumab product and an acceptable safety profile. Differences in the incidence of immune-mediated AEs associated with Pembroria® require further study, considering the duration of observation and sample size. The results support using Pembroria® in routine clinical practice.
- Open Access
- 22 January 2025
- Published by Russian Society of Clinical Oncology in Malignant tumours
- Vol. 14 (4) , 18-28
What we know about the new coronavirus infection in cancer patients
The article presents data from a retrospective study of COVID-19 outcomes in cancer patients from 24 regions of the Russian Federation.The study included 1,055 patients who had a Coronavirus disease 2019, including 451 (42.7 %) men and 604 (57.3) women. The mean age was 58.7 years (29–90); 108 (10.2 %) patients were diagnosed with various comorbidities. 627 (59.4 %) were receiving antitumor drug therapy at the time of diagnosis of COVID-19, and 332 (31.5 %) received antitumor chemotherapy.Most patients had asymptomatic or mild COVID-19: asymptomatic in 205 (19.4 %) patients, and mild — in 517 (49.0 %) patients. Moderate / severe COVID-19 was observed in 268 (25.4 %) patients, while severe / critical COVID-19 was diagnosed in 65 (6.2 %). 1204601776 25 (2.4 %) patients died after COVID-19. The average age of cancer patients who died was 66.3 years (31–84). Among the deceased patients, 16 (64.0 %) were women and 9 (36.0 %) were men. To determine the factors increasing the risk of death in cancer patients we performed univariate and multivariate analyses. Conclusions: based on the presented data, the probability of death from COVID-19 was associated with the anti-tumor therapy administered during the disease. This conclusion obliges us to stop antitumor chemotherapy during the COVID-19 disease.
- 22 January 2025
- Published by Russian Society of Clinical Oncology in Malignant tumours
- Vol. 14 (4) , 18-28
Open AccessWhat we know about the new coronavirus infection in cancer patients
The article presents data from a retrospective study of COVID-19 outcomes in cancer patients from 24 regions of the Russian Federation.The study included 1,055 patients who had a Coronavirus disease 2019, including 451 (42.7 %) men and 604 (57.3) women. The mean age was 58.7 years (29–90); 108 (10.2 %) patients were diagnosed with various comorbidities. 627 (59.4 %) were receiving antitumor drug therapy at the time of diagnosis of COVID-19, and 332 (31.5 %) received antitumor chemotherapy.Most patients had asymptomatic or mild COVID-19: asymptomatic in 205 (19.4 %) patients, and mild — in 517 (49.0 %) patients. Moderate / severe COVID-19 was observed in 268 (25.4 %) patients, while severe / critical COVID-19 was diagnosed in 65 (6.2 %). 1204601776 25 (2.4 %) patients died after COVID-19. The average age of cancer patients who died was 66.3 years (31–84). Among the deceased patients, 16 (64.0 %) were women and 9 (36.0 %) were men. To determine the factors increasing the risk of death in cancer patients we performed univariate and multivariate analyses. Conclusions: based on the presented data, the probability of death from COVID-19 was associated with the anti-tumor therapy administered during the disease. This conclusion obliges us to stop antitumor chemotherapy during the COVID-19 disease.
- Open Access
- 11 November 2024
- Published by Consilium Medicum in Journal of Modern Oncology
- Vol. 26 (3) , 335-340
Cost-effectiveness of using granulocyte colony-stimulating factor in the treatment of uterine body leiomyosarcomas. A retrospective analysis
Background. The main approach in the treatment of patients with uterine leiomyosarcoma is surgery followed by chemotherapy, which is the basis of treatment. Febrile neutropenia (FN) is a life-threatening condition, so the use of granulocyte colony-stimulating factor (G-CSF) after each cycle of chemotherapy in this category of patients remains an integral part. Aim. To evaluate the pharmacoeconomic efficacy of the use of short and long-acting G-CSF forms in a round-the-clock inpatient facility (RIF). Materials and methods. A retrospective analysis of economic expenditures was performed at the Chelyabinsk Regional Clinical Center of Oncology and Nuclear Medicine in the RIF setting for the period from January 2018 to December 2023 for the treatment of 62 patients with high-grade uterine leiomyosarcomas of stage IB–IVA according to the classification of the International Federation of Gynecology and Obstetrics (2009). All patients underwent surgical treatment, complete hysterectomy with appendages, followed by antitumor drug therapy with a high risk of FN. In the economic cost analysis, the treatment regimens gemcitabine 900 mg/m2 on day 1 and day 8 + docetaxel 100 mg/m2 + empegfilgrastim (regimen code sh1207.1) and gemcitabine 900 mg/m2 on day 1 and day 8 + docetaxel 100 mg/m2 + filgrastim (regimen code sh1070) were compared. The costs of clinical blood tests and staying in RIF were also considered. Results. The stay in the RIF was 9 bed days with a long-acting G-CSF regimen and 15 days with a short-acting G-CSF regimen. When using a treatment regimen with filgrastim in 6 patients, the number of bed days increased to 18 due to persistent neutropenia. No FN events were reported. The calculations consisted of the cost of a bed day in the RIF (1,660 rubles) and purchasing of short- and long-acting G-CSF, without the cost of the main therapy. The costs of treating patients with short-acting G-CSF were comparable to those with long-acting G-CSF. Conclusion. The regimen with long-acting G-CSF is effective, easy to use, and cost-effective in RIF settings.
- 11 November 2024
- Published by Consilium Medicum in Journal of Modern Oncology
- Vol. 26 (3) , 335-340
Open AccessCost-effectiveness of using granulocyte colony-stimulating factor in the treatment of uterine body leiomyosarcomas. A retrospective analysis
Background. The main approach in the treatment of patients with uterine leiomyosarcoma is surgery followed by chemotherapy, which is the basis of treatment. Febrile neutropenia (FN) is a life-threatening condition, so the use of granulocyte colony-stimulating factor (G-CSF) after each cycle of chemotherapy in this category of patients remains an integral part. Aim. To evaluate the pharmacoeconomic efficacy of the use of short and long-acting G-CSF forms in a round-the-clock inpatient facility (RIF). Materials and methods. A retrospective analysis of economic expenditures was performed at the Chelyabinsk Regional Clinical Center of Oncology and Nuclear Medicine in the RIF setting for the period from January 2018 to December 2023 for the treatment of 62 patients with high-grade uterine leiomyosarcomas of stage IB–IVA according to the classification of the International Federation of Gynecology and Obstetrics (2009). All patients underwent surgical treatment, complete hysterectomy with appendages, followed by antitumor drug therapy with a high risk of FN. In the economic cost analysis, the treatment regimens gemcitabine 900 mg/m2 on day 1 and day 8 + docetaxel 100 mg/m2 + empegfilgrastim (regimen code sh1207.1) and gemcitabine 900 mg/m2 on day 1 and day 8 + docetaxel 100 mg/m2 + filgrastim (regimen code sh1070) were compared. The costs of clinical blood tests and staying in RIF were also considered. Results. The stay in the RIF was 9 bed days with a long-acting G-CSF regimen and 15 days with a short-acting G-CSF regimen. When using a treatment regimen with filgrastim in 6 patients, the number of bed days increased to 18 due to persistent neutropenia. No FN events were reported. The calculations consisted of the cost of a bed day in the RIF (1,660 rubles) and purchasing of short- and long-acting G-CSF, without the cost of the main therapy. The costs of treating patients with short-acting G-CSF were comparable to those with long-acting G-CSF. Conclusion. The regimen with long-acting G-CSF is effective, easy to use, and cost-effective in RIF settings.
- Open Access
- 10 December 2023
- Published by Consilium Medicum in Journal of Modern Oncology
- Vol. 25 (3) , 373-377
Clinical and economic benefits of parenteral iron carboxymaltosate in patients with gynecological cancers: A retrospective observational study
Background. Timely diagnosis and treatment of iron deficiency anemia in cancer patients affect the quality of life and the effectiveness of anti-tumor treatment. However, choosing a method for correcting anemia is imperative to achieve maximum efficiency and safety with the least financial costs. Aim. To evaluate postoperative methods for treating iron deficiency anemia in patients with gynecological cancers based on a comparative analysis of the clinical and economic outcomes of intravenous iron carboxymaltosate and blood transfusions. Materials and methods. A study of 125 cases of malignant neoplasms of the female reproductive system with a history of iron deficiency anemia was conducted. Study Group 1 included 85 patients with malignancies receiving 500–1000 mg of iron carboxymaltosate (ICM) intravenously; Group 2 included 40 patients with transfusion of packed red cells (PRC). Clinical and economic outcomes of methods for anemia treatment were analyzed. Results. In Group 1, the maximum increase in hemoglobin level was observed from Week 2 of ICM treatment (median increase 1.3 g/dL) peaking by Week 9–10 (median increase 2.3 g/dL). In Group 2 the maximum increase in hemoglobin level was noted at Week 1 after PRC transfusion (median increase 2.1 g/dL), with a gradually decreasing hemoglobin level for 3 weeks after that. No side effects of ICM treatment were reported. In 7 (17.5%) patients, a pyrogenic reaction (hyperthermia) was reported after a blood transfusion. The median time from surgery to the beginning of anti-tumor treatment (radiation therapy, chemotherapy) in Group 1 was 19 days [17; 25] vs. 26 days [22; 30] in Group 2 (p=0.0021). Conclusion. High-dose ICM therapy for iron deficiency anemia in patients with gynecological malignancies is cost-effective and shows a long-term clinical effect.
- 10 December 2023
- Published by Consilium Medicum in Journal of Modern Oncology
- Vol. 25 (3) , 373-377
Open AccessClinical and economic benefits of parenteral iron carboxymaltosate in patients with gynecological cancers: A retrospective observational study
Background. Timely diagnosis and treatment of iron deficiency anemia in cancer patients affect the quality of life and the effectiveness of anti-tumor treatment. However, choosing a method for correcting anemia is imperative to achieve maximum efficiency and safety with the least financial costs. Aim. To evaluate postoperative methods for treating iron deficiency anemia in patients with gynecological cancers based on a comparative analysis of the clinical and economic outcomes of intravenous iron carboxymaltosate and blood transfusions. Materials and methods. A study of 125 cases of malignant neoplasms of the female reproductive system with a history of iron deficiency anemia was conducted. Study Group 1 included 85 patients with malignancies receiving 500–1000 mg of iron carboxymaltosate (ICM) intravenously; Group 2 included 40 patients with transfusion of packed red cells (PRC). Clinical and economic outcomes of methods for anemia treatment were analyzed. Results. In Group 1, the maximum increase in hemoglobin level was observed from Week 2 of ICM treatment (median increase 1.3 g/dL) peaking by Week 9–10 (median increase 2.3 g/dL). In Group 2 the maximum increase in hemoglobin level was noted at Week 1 after PRC transfusion (median increase 2.1 g/dL), with a gradually decreasing hemoglobin level for 3 weeks after that. No side effects of ICM treatment were reported. In 7 (17.5%) patients, a pyrogenic reaction (hyperthermia) was reported after a blood transfusion. The median time from surgery to the beginning of anti-tumor treatment (radiation therapy, chemotherapy) in Group 1 was 19 days [17; 25] vs. 26 days [22; 30] in Group 2 (p=0.0021). Conclusion. High-dose ICM therapy for iron deficiency anemia in patients with gynecological malignancies is cost-effective and shows a long-term clinical effect.
- 3 August 2023
- Published by Media Sphere Publishing Group in P.A. Herzen Journal of Oncology
- Vol. 12 (4)
Approaches to therapy for ovarian cancer yesterday, today, tomorrow
According to the world statistics, ovarian cancer (OC) holds the leading positions in the pattern of cancers. Despite significant advances in its diagnosis and treatment, this cancer is still considered one of the most difficult due to its clinical, biological, and molecular genetic characteristics. This paper will consider key points from the history of the development of approaches to treating OC, as well as will identify the promising areas that will become relevant in the therapy of this disease in the near future.
- 3 August 2023
- Published by Media Sphere Publishing Group in P.A. Herzen Journal of Oncology
- Vol. 12 (4)
Approaches to therapy for ovarian cancer yesterday, today, tomorrow
According to the world statistics, ovarian cancer (OC) holds the leading positions in the pattern of cancers. Despite significant advances in its diagnosis and treatment, this cancer is still considered one of the most difficult due to its clinical, biological, and molecular genetic characteristics. This paper will consider key points from the history of the development of approaches to treating OC, as well as will identify the promising areas that will become relevant in the therapy of this disease in the near future.